Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
$10.04
+1.6%
$9.56
$8.06
$17.19
$134.08M1.6343,502 shs31,423 shs
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$11.36
+4.6%
$8.27
$6.53
$30.60
$103.65M2.75134,471 shs107,170 shs
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
$1.54
-1.9%
$1.48
$0.63
$1.91
$176.44M-0.05475,946 shs179,781 shs
Vaccitech plc stock logo
VACC
Vaccitech
$0.92
-2.6%
$1.57
$1.64
$5.10
$35.51M-0.4244,643 shs16,172 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
0.00%+11.62%+6.42%+13.65%-39.91%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
0.00%+24.78%+56.40%-11.29%-19.10%
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
0.00%-3.75%+9.22%+63.26%+86.67%
Vaccitech plc stock logo
VACC
Vaccitech
0.00%+0.56%-8.80%+21.20%-35.75%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
1.5034 of 5 stars
3.50.00.00.00.63.30.0
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
3.5634 of 5 stars
2.92.00.04.62.80.80.0
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
0.6752 of 5 stars
0.05.00.00.00.61.70.0
Vaccitech plc stock logo
VACC
Vaccitech
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
3.00
Buy$39.00288.64% Upside
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
1.75
Reduce$73.67548.76% Upside
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
0.00
N/AN/AN/A
Vaccitech plc stock logo
VACC
Vaccitech
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest VACC, TLSA, MCRB, and GLSI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/8/2025
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$1.25 ➝ $6.00
4/21/2025
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$38.00 ➝ $39.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/A$0.19 per shareN/A
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$126.32M0.78N/AN/A$1.61 per share7.05
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/AN/AN/AN/A$0.04 per shareN/A
Vaccitech plc stock logo
VACC
Vaccitech
$13.42M2.64$0.05 per share19.30$6.52 per share0.14
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$15.79M-$1.26N/AN/AN/AN/A-450.87%-333.18%8/12/2025 (Estimated)
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$140K-$4.60N/AN/AN/AN/A-41,084.76%-55.87%8/12/2025 (Estimated)
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
-$11.86MN/A0.00N/AN/AN/AN/A8/5/2025 (Estimated)
Vaccitech plc stock logo
VACC
Vaccitech
$5.34M-$1.43N/AN/AN/A-409.18%-23.41%-20.85%N/A

Latest VACC, TLSA, MCRB, and GLSI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/20/2025Q1 2025
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$0.24-$0.25-$0.01-$0.25N/AN/A
5/7/2025Q1 2025
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
-$0.67-$2.24-$1.57$3.75$10.00 millionN/A
4/15/2025Q4 2024
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$0.21-$0.61-$0.40-$0.61N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/AN/A
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
N/AN/AN/AN/AN/A
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/AN/AN/AN/AN/A
Vaccitech plc stock logo
VACC
Vaccitech
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/A
1.91
1.91
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
N/A
2.11
2.11
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/A
1.02
1.02
Vaccitech plc stock logo
VACC
Vaccitech
N/A
15.26
15.26

Institutional Ownership

CompanyInstitutional Ownership
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
4.16%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
59.34%
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/A
Vaccitech plc stock logo
VACC
Vaccitech
26.13%

Insider Ownership

CompanyInsider Ownership
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
51.67%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
4.70%
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
39.82%
Vaccitech plc stock logo
VACC
Vaccitech
6.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
313.37 million6.46 millionNot Optionable
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
3308.73 million8.32 millionOptionable
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
8116.85 million70.32 millionOptionable
Vaccitech plc stock logo
VACC
Vaccitech
3338.55 million36.23 millionNot Optionable

Recent News About These Companies

10 Startups Founded Out Of Oxford University
BRNS Stock Earnings: Barinthus Biotherapeutics Misses EPS for Q2 2024
How real are the threats to the US dollar?
Google invests in UK vaccine pioneer Vaccitech
News - Leon Hooftman

New MarketBeat Followers Over Time

Media Sentiment Over Time

Greenwich LifeSciences stock logo

Greenwich LifeSciences NASDAQ:GLSI

$10.04 +0.16 (+1.57%)
As of 07/3/2025 03:12 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Seres Therapeutics stock logo

Seres Therapeutics NASDAQ:MCRB

$11.36 +0.50 (+4.56%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$11.94 +0.58 (+5.11%)
As of 07/3/2025 04:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Tiziana Life Sciences stock logo

Tiziana Life Sciences NASDAQ:TLSA

$1.54 -0.03 (-1.91%)
As of 07/3/2025 03:23 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

Vaccitech stock logo

Vaccitech NASDAQ:VACC

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.